HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $180.

March 04, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Axsome Therapeutics with a $180 price target.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in AXSM's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100